9SO Stock Chart & Stats
€0.14
<€0.01(2.88%)
At close: 4:00 PM EST
€0.14
<€0.01(2.88%)
Day’s Range― - ―
52-Week Range€0.09 - €0.22
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€44.42M
Enterprise Value€5.89K
Total Cash (Recent Filing)€1.29B
Total Debt (Recent Filing)€78.00M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding273,414,370
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€10.59M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageVery low leverage gives Solasia greater financial flexibility than a highly indebted development-stage pharmaceutical company. Limited debt reduces near-term interest and refinancing pressure, helping preserve capacity to fund oncology development and partnerships even while profitability remains weak.
Improved Gross MarginThe move to a positive gross margin indicates that the company’s underlying product economics improved materially from 2024. If sustained, better gross profitability could provide a stronger foundation for partnerships, commercialization, and eventual operating leverage as revenue scales.
Partnered Oncology Business ModelA collaboration- and licensing-led model can extend Solasia’s commercialization reach while allowing partner-funded development, milestones, royalties, or profit sharing to contribute to economics. Its oncology and supportive-care focus also targets persistent medical needs and supports a specialized strategic position.
Bears Say
Persistent Cash BurnNegative operating and free cash flow across all reported periods shows that the business is not currently self-funding. Continued cash consumption increases dependence on future financing or partner support, while sustained funding needs could reduce strategic flexibility and create dilution risk.
Deep And Persistent LossesThe scale and persistence of losses indicate that current sales are insufficient to cover the company’s cost structure. Without demonstrated operating leverage or a path to breakeven, ongoing deficits can erode equity, constrain investment capacity, and make durable profitability dependent on successful future development outcomes.
Volatile, Recently Declining RevenueRecent revenue contraction and earlier volatility make the top line an uncertain base for scaling the business. Unstable sales can limit royalty and product income, complicate cost planning, and delay the operating leverage needed to offset persistent research, development, and corporate expenses.
Solasia Pharma KK News
9SO FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was €0.09 and its highest was €0.22 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is €44.42M.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Nov 16, 2026 which is in 63 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on Aug 13, 2026. The company reported -€0.005 earnings per share for the quarter.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in DE:9SO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―